Why Accenture, Applovin, and Cognizant Shares Fell
The consulting business faces substantial headwinds. Artificial intelligence might render consulting work from Accenture (ACN) unnecessary. For example, companies might use AI to generate project management schedules and strategy documents. That would save them from paying consulting fees.In its fiscal Q3 report, Accenture reported revenue of $17.7 billion, up by 7.5% Y/Y. GAAP EPS was $3.49, beating expectations. Despite increasing its free cash flow target for the year to $9 billion to $9.7 billion, ACN shares sold off.AppLovin (APP) lost 12.02% in the last week. Although bears collectively hold a 3.43% short float against APP stock, a Culper Research short report spooked investors. The firm speculated that the firm has the backing of Chinese shareholders and their operations. AppLovin denied those claims.APP stock has a strong chance of staging a powerful rebound. Historically, the stock would rally in double-digit percentages on any good news.Cognizant (CTSH) traded at $80 for many weeks before falling by 4.64% on June 20. In April, the firm detailed its strategic progress in AI. It generated 1,400 active generative AI engagements. It also established a partnership with Nvidia (NVDA). The downtick in CTSH stock is unusual. However, Accenture’s drop likely hurt Cognizant’s share price. Expect value investors to add to their CTSH stock position.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


